A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors.

Trial Profile

A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2012

At a glance

  • Drugs EMD 1204831 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 27 Jun 2012 Actual patients number is 38 as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top